Zinc lozenges for colds: the form and the timing decide everything
Zinc trials for the common cold disagree wildly, and the split traces back to what was in the lozenge and when someone started it, not whether zinc works at all.

Zinc lozenges shortened colds by roughly one to three days in trials where people started them once symptoms began.1,2 The size of the gain depended on the zinc compound, the dose, and how early the first lozenge came. Zinc did little to stop people catching a cold in the first place.3
Why the same question gets different answers
Researchers have tested zinc against colds since the 1980s, and the trials still disagree. A 2024 Cochrane review pooled 34 studies with 8,526 people. Fifteen tested prevention and 19 tested treatment.3 Taken to prevent colds, zinc cut the risk of catching one only slightly, and the range included no effect at all.3 Taken to treat a cold already under way, it shortened the cold by 2.37 days on average.3
That split is the first reason headlines contradict each other. One trial asks whether daily zinc stops you getting sick. Another asks whether zinc at the first sniffle ends a cold sooner. Both get reported as "the zinc study." The review also graded the treatment evidence low certainty, because the 8 trials behind it disagreed widely with one another.3
The form in the lozenge is not one thing
Even among treatment trials, "zinc lozenge" hides real differences. Of the 34 studies, 17 used lozenges. They came in acetate, gluconate and orotate forms, and gluconate was the most common, in 9 of the 17.3 Doses of zinc gluconate ranged from 45 to 276 milligrams a day, taken for 4.5 to 21 days.3
That is a wide spread to average into one number. A low dose for a few days and a high dose for three weeks are different products, filed under one name.
Low doses fared worst. One pair of trials gave lozenges with 13.3 milligrams of zinc gluconate or 5 to 11.5 milligrams of zinc acetate. In colds that people caught naturally, neither form changed how long symptoms lasted.6 Gluconate did shorten colds that the researchers had started with a virus on purpose, 2.5 days against 3.5 for placebo.6 The older Cochrane review found a clear benefit only at 75 milligrams a day or more.2
The pools above come from different slices of the evidence. One analysis of zinc taken alone, without other supplements, found colds ran 2.25 days shorter.4 The 2024 review's treatment trials gave 2.37 days.3 The older Cochrane review of 16 therapeutic trials found a smaller effect, about one day.2 The largest, tightest effect came from the acetate lozenges, at 2.73 days.1
A different form also flopped. In a trial of 77 volunteers, a zinc gluconate nasal spray plus orotate lozenges did nothing. After 7 days, 63 percent of the zinc group had no symptoms, against 53 percent on placebo.7 Some people in the zinc group also had pain inside the nose.7
Zinc acetate has the most consistent record
Zinc acetate has the cleanest evidence, largely because researchers went back to the original records of three acetate trials, not just the published averages. The 199 patients in those trials had colds that lasted about 7 days on average. Zinc acetate lozenges shortened them by 2.73 days, close to two-fifths of the whole illness.1
The effect held up whether someone had allergies, smoked, was older or younger, or was male or female. It did not change with how bad the cold was at the start.1 The authors said that made the result look applicable across a wide range of cold sufferers.1
A separate analysis of the same trials, using doses of 80 to 92 milligrams a day, broke the effect down by symptom. Cough ran 46 percent shorter, hoarseness 43 percent, nasal congestion 37 percent and nasal discharge 34 percent. Headache and fever did not change.5 Sore throat, at 18 percent, had a range that crossed zero.5 The authors suggested the benefit may relate to how much zinc reaches the throat from a dissolving lozenge.5
Timing matters as much as the pill
The older Cochrane review put it plainly. Zinc taken within 24 hours of the first symptom reduced how long the cold lasted, though the trials varied enough that the average needs caution.2 The acetate authors likewise described lozenges started within 24 hours and used for less than two weeks.5
None of the abstracts tested what happens if someone waits until day three. A bottle opened late in a cold is not the situation these numbers describe.
The side that gets left out of the headline
Zinc lozenges have downsides. In the older Cochrane pooling, the odds of a bad taste were 2.31 times higher with zinc than placebo. The odds of nausea were 2.15 times higher.2 The 2024 review found a higher risk of non-serious side effects when zinc treated an active cold, a risk ratio of 1.34, which it rated moderate certainty.3
That trade-off rarely reaches a bottle's marketing, where the number is duration and the taste is an afterthought. It belongs in the same sentence as the day count.
What remains unknown
The clearest gap is dose. Nobody has cleanly separated how much of the benefit tracks with the dose and how much with the acetate or gluconate form itself.3 The acetate pooling is the tidiest evidence, but it rests on three trials and 199 patients.1
What holds across the reviews is narrower than the marketing. Zinc as a lozenge, at a substantial daily dose, started within a day of the first symptom, shortened colds in these trials by one to three days. Prevention, low doses and late starts are a different and weaker story.
QUESTIONS THIS POST ANSWERS
- Which type of zinc lozenge did the trials use?
- Most lozenge trials used zinc acetate, zinc gluconate, or zinc orotate, with gluconate the most common. In the 2024 Cochrane review, zinc gluconate doses ranged from 45 to 276 milligrams a day, taken for 4.5 to 21 days. Form and dose varied enough between trials that comparing results directly is difficult.
- Can zinc cause nausea or a metallic taste?
- Yes, and these are the most consistent side effects in the trials. In a 2013 Cochrane review, the odds of a bad taste were 2.31 times higher with zinc than placebo, and the odds of nausea were 2.15 times higher. A 2024 review found a higher risk of non-serious side effects when zinc was used to treat an active cold.
REFERENCES
Each reference was re-checked against PubMed before publication. How sources are checked
- 1Hemilä H, et al. Zinc acetate lozenges for treating the common cold: an individual patient data meta-analysis. British journal of clinical pharmacology. 2016. Source
- 2Singh M, et al. Zinc for the common cold. The Cochrane database of systematic reviews. 2013. Source
- 3Nault D, et al. Zinc for prevention and treatment of the common cold. The Cochrane database of systematic reviews. 2024. Source
- 4Wang MX, et al. Zinc Supplementation Reduces Common Cold Duration among Healthy Adults: A Systematic Review of Randomized Controlled Trials with Micronutrients Supplementation. The American journal of tropical medicine and hygiene. 2020. Source
- 5Hemilä H, Chalker E. The effectiveness of high dose zinc acetate lozenges on various common cold symptoms: a meta-analysis. BMC family practice. 2015. Source
- 6Turner RB, et al. Effect of treatment with zinc gluconate or zinc acetate on experimental and natural colds. Clinical infectious diseases. 2000. Source
- 7Eby GA, et al. Ineffectiveness of zinc gluconate nasal spray and zinc orotate lozenges in common-cold treatment: a double-blind, placebo-controlled clinical trial. Alternative therapies in health and medicine. 2006. Source